Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease.

ABSTRACT:

Objective

To determine the safety and pharmacokinetics of etanercept (Amgen, Thousand Oaks, California) a tumor necrosis factor-α receptor blocker, in children with acute Kawasaki disease (KD). Standard therapy of acute KD includes intravenous immunoglobulin (IVIG) and high-dose aspirin, but a substantial number of patients are refractory and require additional treatment. Tumor necrosis factor-α levels are elevated in children with KD, suggesting a role for etanercept in treatment.

Study design

We performed a prospective open-label trial of etanercept in patients with KD (age range, 6 months-5 years; n = 17) meeting clinical criteria and with fever ≤ 10 days. All received IVIG and high-dose aspirin. They received etanercept immediately after IVIG infusion and then weekly two

SUBMITTER: Choueiter NF 

PROVIDER: S-EPMC2970727 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature